Joel Isaacson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Joel Isaacson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$321K	Buy	614 +39	+7%	+$20K	0.01%	387
2026 Q2	$286K	Buy	575 +69	+14%	+$30.6K	0.01%	392
2026 Q1	$226K	Buy	506 +14	+3%	+$6.53K	0.01%	413
2025 Q4	$223K	Buy	+492	New	+$212K	0.01%	419
2025 Q3	–	Sell	-454	Closed	-$202K	–	455
2025 Q2	$202K	Hold	454	–	–	0.01%	401
2025 Q1	$220K	Buy	+454	New	+$212K	0.01%	362
2024 Q3	–	Sell	-469	Closed	-$220K	–	379
2024 Q2	$220K	Buy	+469	New	+$204K	0.01%	317
2015 Q3	–	Sell	-1,150	Closed	-$142K	–	777
2015 Q2	$142K	Hold	1,150	–	–	0.04%	210
2015 Q1	$136K	Hold	1,150	–	–	0.03%	215
2014 Q4	$137K	Buy	+1,150	New	+$130K	0.04%	197

Other funds holding VRTX

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Joel Isaacson & Co's VRTX Position: Q3 2026 in Review

Joel Isaacson & Co increased its Vertex Pharmaceuticals (VRTX) stake by 6.8% in Q3 2026, buying an estimated $20K and bringing the position to 614 shares worth $321K. The position accounts for 0.01% of the portfolio, ranked #387.

Joel Isaacson & Co first reported a position in VRTX in Q4 2014 and has held it in 10 quarters since. 930 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Joel Isaacson & Co held 614 shares of Vertex Pharmaceuticals worth $321K as of Q3 2026.
Joel Isaacson & Co bought 39 Vertex Pharmaceuticals shares in Q3 2026, an estimated $20K.
Vertex Pharmaceuticals made up 0.01% of Joel Isaacson & Co's portfolio in Q3 2026, its #387 holding.
Joel Isaacson & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
930 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Joel Isaacson & Co's 13F filing for Q3 2026, filed 5 Nov 2026.